Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.
A three-year clinical trial was halted after Merck admitted the study showed participants had double the risk of a heart attack compared to those taking a placebo. “We’re taking this action because we believe it best serves the interest of patients,” Ray V. Gilmartin, Merck’s chairman, president and chief executive, said in a statement.
